Xenobiotic

Xenobiotic designates any chemical substance that is foreign to a living organism and not naturally produced within the body, including medicines, industrial chemicals, pollutants, pesticides, food additives, and other exogenous compounds. These substances are distinguished from endogenous molecules by their external origin and often require specialised biological handling to prevent accumulation and toxicity. Xenobiotic processing typically involves Phase I reactions such as oxidation, reduction, or hydrolysis mediated by cytochrome P450 enzymes, followed by Phase II conjugation reactions increasing water solubility for elimination.

In biopharmaceutical development, xenobiotics are central to pharmacology and toxicology because they undergo metabolism and clearance pathways that determine exposure, efficacy, and safety. Xenobiotic studies support prediction of drug-drug interactions, identification of reactive metabolites, and evaluation of organ-specific toxicity risks. Regulatory submissions require comprehensive characterisation of xenobiotic metabolism, including major metabolites and their safety relevance. Pharmacogenomic considerations address genetic variants affecting xenobiotic metabolism, influencing drug responses and toxicity risks. Environmental assessment evaluates pharmaceutical xenobiotics persisting after patient excretion, assessing ecological impacts. Species differences in xenobiotic metabolism affect preclinical model relevance and human prediction. As understanding deepens regarding xenobiotic metabolism mechanisms and computational approaches improve prediction, xenobiotic science continues informing development through comprehensive metabolism characterisation and toxicity assessment.